WNT2 and colorectal carcinoma: A study of WNT2 in both OSCC and CRC allograft tumors found that anti-WNT2, which suppresses antitumor T-cell response in DC via the SOCS3/p-JAK2/p-STAT3 signaling cascades, enhances the therapeutic response in anti-PD1 therapy [63].